Sunobinop

About Imbrium Therapeutics

Imbrium Therapeutics is a U.S.-based, clinical-stage biotech company, wholly owned by Purdue Pharma L.P., which is undergoing a court-approved bankruptcy reorganization. The company's strategic focus is on developing first-in-class small molecule therapies for high-need areas, including glioblastoma and non-opioid pain. Its lead asset, tinostamustine, is in clinical development for glioblastoma, representing a novel dual-mechanism approach. The firm's future is contingent on the successful emergence of the restructured Knoa Pharma entity from bankruptcy, which will determine its operational and financial trajectory.

Therapeutic Areas

Other Not specified Drugs